Drugs in the Pipeline
Imbruvica Under Review for Graft-Versus-Host-Disease
Imbruvica is a first-in-class, oral Bruton's tyrosine kinase (BTK) inhibitor.
Your search for oral corticosteroids returned 2 results
Drugs in the Pipeline
Rituxan Gets Breakthrough Therapy Status for Rare Autoimmune Skin Disorder
Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
